- Home
- All Stock List
- BSE
- Wockhardt Ltd Share Price
1,526.00
33.45 (2.24%)
-
Outperforms Index
193.04%
Return (1Y)
Beaten BSE Healthcare by 168.96%
-
More Volatile
3.69%
Standard Deviation (1Y)
Higher than BSE Healthcare by 2.63%
-
Consistent Performer
8/12
Months
beaten BSE Healthcare
-
AxisDirect View
No View
1,679

489
News & Announcements
-
Wockhardt reports consolidated net loss of Rs 25.00 crore in the March 2025 quarter
29 - May - 2025 12:00 | 7 days ago
Net Loss of Wockhardt reported to Rs 25.00 crore in the quarter ended March 2025 as against net loss of Rs 169.00 crore during the previous quarter ended March 2024. Sales rose 6.14% to Rs 743.00 crore in the quarter ended March 2025 as against Rs 700.00 crore during the previous quarter ended March 2024.
For the full year,net loss reported to Rs 47.00 crore in the year ended March 2025 as against net loss of Rs 463.00 crore during the previous year ended March 2024. Sales rose 7.65% to Rs 3012.00 crore in the year ended March 2025 as against Rs 2798.00 crore during the previous year ended March 2024.
Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 743.00 700.00 6 3012.00 2798.00 8 OPM % 8.61 -8.43 - 13.05 3.25 - PBDT 31.00 -78.00 LP 201.00 -131.00 LP PBT -22.00 -136.00 84 -16.00 -354.00 95 NP -25.00 -169.00 85 -47.00 -463.00 90 Powered by Capital Market - Live News
-
Wockhardt to conduct board meeting
12 days ago
-
Wockhardt announces incorporation of step-down subsidiary in Ireland
08 - Apr - 2025 12:00 | 58 days ago
Wockhardt Bio AG, a subsidiary of Wockhardt, has incorporated a new Wholly Owned Subsidiary in Ireland by the name Wockhardt Antibiotics (Ireland). Consequent to the incorporation, Wockhardt Antibiotics (Ireland) has become a Step-Down Subsidiary of the Company.
Powered by Capital Market - Live News
-
Wockhardt to conduct board meeting
12 days ago
-
Wockhardt announces incorporation of step-down subsidiary in Ireland
08 - Apr - 2025 12:00 | 58 days ago
Wockhardt Bio AG, a subsidiary of Wockhardt, has incorporated a new Wholly Owned Subsidiary in Ireland by the name Wockhardt Antibiotics (Ireland). Consequent to the incorporation, Wockhardt Antibiotics (Ireland) has become a Step-Down Subsidiary of the Company.
Powered by Capital Market - Live News
-
Wockhardt surges after breakthrough US cancer treatment with Zaynich
01 - Apr - 2025 12:00 | 65 days ago
The 15-year-old patient, diagnosed with Acute Myeloid Leukemia (AML), had been battling a life-threatening blood and liver infection resistant to nine different antibiotics over 45 days. The infection, caused by NDM-producing E. coli, persisted despite treatment with multiple last-resort antibiotics, including Tigecycline, Polymyxin B, and Ceftazidime/avibactam + Aztreonam.
With limited treatment options left, doctors at St. Jude?s Hospital, Memphis, USA, sought compassionate use approval from the US FDA to administer Zaynich. Over 41 days of treatment, the patient made a full recovery, marking the third successful US case treated with Wockhardt's novel β-lactam enhancer antibiotic.
Zaynich, a proprietary β-lactam enhancer antibiotic, has now been used under compassionate use in 51 critically ill patients globally, demonstrating its potential against multi-drug resistant Gram-negative infections. The drug recently completed Phase III global trials, paving the way for marketing approvals worldwide.
Wockhardt is a research based global pharmaceutical and biotech company.
The company reported consolidated net profit of Rs 14 crore in Q3 FY25 as against net loss of Rs 83 crore in Q3 FY24. Net sales rose 2.9% year on year to Rs 721 crore in Q3 FY25.
Powered by Capital Market - Live News
-
Wockhardt reports consolidated net loss of Rs 25.00 crore in the March 2025 quarter
29 - May - 2025 12:00 | 7 days ago
Net Loss of Wockhardt reported to Rs 25.00 crore in the quarter ended March 2025 as against net loss of Rs 169.00 crore during the previous quarter ended March 2024. Sales rose 6.14% to Rs 743.00 crore in the quarter ended March 2025 as against Rs 700.00 crore during the previous quarter ended March 2024.
For the full year,net loss reported to Rs 47.00 crore in the year ended March 2025 as against net loss of Rs 463.00 crore during the previous year ended March 2024. Sales rose 7.65% to Rs 3012.00 crore in the year ended March 2025 as against Rs 2798.00 crore during the previous year ended March 2024.
Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 743.00 700.00 6 3012.00 2798.00 8 OPM % 8.61 -8.43 - 13.05 3.25 - PBDT 31.00 -78.00 LP 201.00 -131.00 LP PBT -22.00 -136.00 84 -16.00 -354.00 95 NP -25.00 -169.00 85 -47.00 -463.00 90 Powered by Capital Market - Live News
-
Wockhardt to conduct board meeting
12 days ago
-
Wockhardt announces incorporation of step-down subsidiary in Ireland
08 - Apr - 2025 12:00 | 58 days ago
Wockhardt Bio AG, a subsidiary of Wockhardt, has incorporated a new Wholly Owned Subsidiary in Ireland by the name Wockhardt Antibiotics (Ireland). Consequent to the incorporation, Wockhardt Antibiotics (Ireland) has become a Step-Down Subsidiary of the Company.
Powered by Capital Market - Live News
-
Wockhardt surges after breakthrough US cancer treatment with Zaynich
01 - Apr - 2025 12:00 | 65 days ago
The 15-year-old patient, diagnosed with Acute Myeloid Leukemia (AML), had been battling a life-threatening blood and liver infection resistant to nine different antibiotics over 45 days. The infection, caused by NDM-producing E. coli, persisted despite treatment with multiple last-resort antibiotics, including Tigecycline, Polymyxin B, and Ceftazidime/avibactam + Aztreonam.
With limited treatment options left, doctors at St. Jude?s Hospital, Memphis, USA, sought compassionate use approval from the US FDA to administer Zaynich. Over 41 days of treatment, the patient made a full recovery, marking the third successful US case treated with Wockhardt's novel β-lactam enhancer antibiotic.
Zaynich, a proprietary β-lactam enhancer antibiotic, has now been used under compassionate use in 51 critically ill patients globally, demonstrating its potential against multi-drug resistant Gram-negative infections. The drug recently completed Phase III global trials, paving the way for marketing approvals worldwide.
Wockhardt is a research based global pharmaceutical and biotech company.
The company reported consolidated net profit of Rs 14 crore in Q3 FY25 as against net loss of Rs 83 crore in Q3 FY24. Net sales rose 2.9% year on year to Rs 721 crore in Q3 FY25.
Powered by Capital Market - Live News
-
Wockhardt reports consolidated net loss of Rs 25.00 crore in the March 2025 quarter
29 - May - 2025 12:00 | 7 days ago
Net Loss of Wockhardt reported to Rs 25.00 crore in the quarter ended March 2025 as against net loss of Rs 169.00 crore during the previous quarter ended March 2024. Sales rose 6.14% to Rs 743.00 crore in the quarter ended March 2025 as against Rs 700.00 crore during the previous quarter ended March 2024.
For the full year,net loss reported to Rs 47.00 crore in the year ended March 2025 as against net loss of Rs 463.00 crore during the previous year ended March 2024. Sales rose 7.65% to Rs 3012.00 crore in the year ended March 2025 as against Rs 2798.00 crore during the previous year ended March 2024.
Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 743.00 700.00 6 3012.00 2798.00 8 OPM % 8.61 -8.43 - 13.05 3.25 - PBDT 31.00 -78.00 LP 201.00 -131.00 LP PBT -22.00 -136.00 84 -16.00 -354.00 95 NP -25.00 -169.00 85 -47.00 -463.00 90 Powered by Capital Market - Live News
-
Wockhardt to conduct board meeting
12 days ago
-
Wockhardt announces incorporation of step-down subsidiary in Ireland
08 - Apr - 2025 12:00 | 58 days ago
Wockhardt Bio AG, a subsidiary of Wockhardt, has incorporated a new Wholly Owned Subsidiary in Ireland by the name Wockhardt Antibiotics (Ireland). Consequent to the incorporation, Wockhardt Antibiotics (Ireland) has become a Step-Down Subsidiary of the Company.
Powered by Capital Market - Live News
-
Wockhardt to conduct board meeting
12 days ago
-
Wockhardt announces incorporation of step-down subsidiary in Ireland
08 - Apr - 2025 12:00 | 58 days ago
Wockhardt Bio AG, a subsidiary of Wockhardt, has incorporated a new Wholly Owned Subsidiary in Ireland by the name Wockhardt Antibiotics (Ireland). Consequent to the incorporation, Wockhardt Antibiotics (Ireland) has become a Step-Down Subsidiary of the Company.
Powered by Capital Market - Live News
-
Wockhardt surges after breakthrough US cancer treatment with Zaynich
01 - Apr - 2025 12:00 | 65 days ago
The 15-year-old patient, diagnosed with Acute Myeloid Leukemia (AML), had been battling a life-threatening blood and liver infection resistant to nine different antibiotics over 45 days. The infection, caused by NDM-producing E. coli, persisted despite treatment with multiple last-resort antibiotics, including Tigecycline, Polymyxin B, and Ceftazidime/avibactam + Aztreonam.
With limited treatment options left, doctors at St. Jude?s Hospital, Memphis, USA, sought compassionate use approval from the US FDA to administer Zaynich. Over 41 days of treatment, the patient made a full recovery, marking the third successful US case treated with Wockhardt's novel β-lactam enhancer antibiotic.
Zaynich, a proprietary β-lactam enhancer antibiotic, has now been used under compassionate use in 51 critically ill patients globally, demonstrating its potential against multi-drug resistant Gram-negative infections. The drug recently completed Phase III global trials, paving the way for marketing approvals worldwide.
Wockhardt is a research based global pharmaceutical and biotech company.
The company reported consolidated net profit of Rs 14 crore in Q3 FY25 as against net loss of Rs 83 crore in Q3 FY24. Net sales rose 2.9% year on year to Rs 721 crore in Q3 FY25.
Powered by Capital Market - Live News
Stock Trivia
Wockhardt Ltd has been the 3rd best in 1 years performance among stocks in Pharmaceuticals Sector
FII shareholding in Wockhardt Ltd has increased by 24.05% since past 1 Year
Wockhardt Ltd has been the 3rd best in 1 years performance among stocks in Pharmaceuticals Sector
FII shareholding in Wockhardt Ltd has increased by 4.09% since past 3 Months
MF shareholding in Wockhardt Ltd has increased by 6.11% since past 3 Months
FII shareholding in Wockhardt Ltd has increased by 24.05% since past 1 Year
Wockhardt Ltd has been the 3rd best in 1 years performance among stocks in Pharmaceuticals Sector
FII shareholding in Wockhardt Ltd has increased by 24.05% since past 1 Year
